MAXHEALTH
Max Healthcare Institute Limited
Each stock's 10,000-path forecast, rendered as light.
Max Healthcare Institute Limited (MAXHEALTH) Stock Analysis & Case Study
Is MAXHEALTH a good buy? The data-driven verdict.
Max Healthcare Institute Limited (MAXHEALTH) trades at ₹1,070,on the numbers it mixed signals, a Downstox Snapshot Score of 49/100.
On the numbers, Max Healthcare Institute Limited (MAXHEALTH) mixed signals, a Downstox Snapshot Score of 49/100, weighing expensive at 70.2× earnings, ROE of 14.7%, a 61% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
MAXHEALTH fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How MAXHEALTH ranks against the 2,373 companies in our screener
- MAXHEALTH's market cap of 1.04L Cr ranks in the top 5% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- MAXHEALTH's book value of ₹110 ranks in the 55th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- MAXHEALTH's promoter holding of 23.7% ranks in the bottom 4% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- MAXHEALTH's 3-year profit (PAT) growth of 10.0% ranks in the 42nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- MAXHEALTH's 3-year revenue growth of 22.0% ranks in the 76th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- MAXHEALTH's debt-to-equity ratio of 0.32x is lower than 49% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is MAXHEALTH overvalued? MAXHEALTH P/E vs peers
MAXHEALTH trades at 70.2× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
MAXHEALTH share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 5.9y of MAXHEALTH history (39%/yr drift, 31%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| MAXHEALTH 2027 | ₹783 | ₹1,170 | ₹1,748 | +9% |
| MAXHEALTH 2028 | ₹723 | ₹1,280 | ₹2,265 | +20% |
| MAXHEALTH 2029 | ₹708 | ₹1,400 | ₹2,770 | +31% |
| MAXHEALTH 2030 | ₹690 | ₹1,531 | ₹3,399 | +43% |
| MAXHEALTH 2031 | ₹683 | ₹1,675 | ₹4,104 | +57% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability MAXHEALTH goes up, or doubles?
The bull case for MAXHEALTH
- MAXHEALTH's return on equity of 14.7% ranks in the 70th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- A 10,000-path probability model puts a 61% chance the price is higher in a year, with a median target of ₹1,170 (+9%).
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹2,770.
The bear case & risks
- MAXHEALTH's P/E of 70.2x is lower than 17% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- A steep 9.7× price-to-book means most of the value is intangible/expectations, not assets on the books.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹708.
MAXHEALTH volatility & expected range, how bumpy is the ride?
Over the last 5.9 years MAXHEALTH compounded at 39%/year with annualized volatility of 31%. That volatility implies a 1-year 80% range of ₹783-₹1,748, the honest backbone behind any single price target.
MAXHEALTH price forecast, the full 60-month probability fan
MAXHEALTH price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds MAXHEALTH hits common targets within the simulated horizon?
Full multi-horizon detail on the MAXHEALTH price target & forecast page.
MAXHEALTH Piotroski F-Score: 6/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. MAXHEALTH scores 6/8, mixed financial health.
MAXHEALTH MTF margin & leverage across 10 brokers
Margin Trading Facility lets you buy MAXHEALTH with part of the capital. Lower margin % = higher leverage. Rates compared across 10 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 25.77% | 3.9× |
| Zerodha | 24.90% | 4.0× |
| Groww | 24.98% | 4.0× |
| Dhan | 24.00% | 4.2× |
| Kotak NeoCHEAPEST | 22.22% | 4.5× |
| Paytm Money | 23.20% | 4.3× |
| Pocketful | 29.48% | 3.4× |
| Anand Rathi | 29.23% | 3.4× |
| Bajaj Broking | 25.00% | 4.0× |
| Share India | 29.31% | 3.4× |
Compare every broker on the MAXHEALTH MTF page.
About Max Healthcare Institute Limited: sector, index & market-cap context
Max Healthcare Institute Limited (MAXHEALTH) is a large-cap NSE-listed company in the Healthcare sector, and a constituent of the Nifty 50 index, with a market capitalisation of ₹1.04L Cr. See more stocks on our screener.
How the MAXHEALTH Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Max Healthcare Institute Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
MAXHEALTH analysis, FAQs
Is Max Healthcare Institute Limited (MAXHEALTH) a good buy?
On the numbers, Max Healthcare Institute Limited (MAXHEALTH) mixed signals, a Downstox Snapshot Score of 49/100, weighing expensive at 70.2× earnings, ROE of 14.7%, a 61% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is MAXHEALTH overvalued or undervalued?
MAXHEALTH trades at 70.2× earnings, expensive versus the ~22× long-run Nifty average.
What is the MAXHEALTH share price target for 2031?
MAXHEALTH's probability-weighted 2031 median target is ₹1,675, with an 80% range of ₹683-₹4,104 (10,000-path Monte-Carlo).
What is the probability MAXHEALTH doubles in 5 years?
The modelled probability of MAXHEALTH reaching ₹2,140 (2×) within 5 years is 36%.
What is the bull case for MAXHEALTH?
MAXHEALTH's return on equity of 14.7% ranks in the 70th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026. A 10,000-path probability model puts a 61% chance the price is higher in a year, with a median target of ₹1,170 (+9%).
What are the risks in MAXHEALTH?
MAXHEALTH's P/E of 70.2x is lower than 17% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. A steep 9.7× price-to-book means most of the value is intangible/expectations, not assets on the books.